Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: To report results at week 208, including a 104‐week masked extension, of the EMPA‐REG H2H‐SU trial in patients with type 2 diabetes with inadequate glycaemic control on metformin, in which empagliflozin 25 mg given for 104 weeks provided a sustained reduction in glycated haemoglobin (HbA1c) with a small but statistically significant benefit vs glimepiride, sustained reductions in weight and blood pressure, and low risk of hypoglycaemia. Research Design and Methods: Patients with type 2 diabetes and HbA1c 53‐86 mmol/mol (7% to 10%) were randomized to empagliflozin 25 mg or glimepiride 1 to 4 mg for 104 weeks as add‐on to metformin. Patients who completed the randomized treatment period could participate in a 104‐week extension in which they continued the double‐blind treatment allocated at randomization. Results: Of 765 and 780 patients treated with empagliflozin and glimepiride, 576 and 549 patients, respectively, entered the extension period of the study. At week 208, the adjusted mean difference in change from baseline in HbA1c with empagliflozin vs glimepiride was −1.96 mmol/mol, 95% CI −3.57, −0.35 (−0.18%, 95% CI −0.33, −0.03); P = 0.0172. Rescue therapy was given to 23% of patients on empagliflozin and 34% on glimepiride (odds ratio 0.56 [95% CI 0.45, 0.71]; P < 0.0001). Confirmed hypoglycaemic adverse events (plasma glucose ≤3.9 mmol/L and/or requiring assistance) occurred in 3% of patients on empagliflozin and 28% on glimepiride (odds ratio 0.08 [95% CI 0.05, 0.13]; P < 0.0001). Conclusions: In patients with type 2 diabetes, empagliflozin 25 mg as add‐on to metformin for 208 weeks reduced HbA1c with a significantly lower risk of hypoglycaemia and a significantly smaller proportion of patients receiving rescue therapy compared with glimepiride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · cited 1×
“higher doses should generally be avoided because of the risk of hypoglycaemia.(20,21) In conclusion, when given to patients with type 2 diabetes as”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 2×
“These observations are consistent with the results of the EMPA-REG OUTCOME trial, in which the initial decrease in eGFR with empagliflozin was reversed after cessation of study drug and mean eGFR was significantly higher compared with placebo at the follow-up visit.(10) This pattern of change in eGFR suggests that the…”
BackgroundResultSelf-citationBody Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“This constitutes a clinically meaningful advantage of empagliflozin over glimepiride, as hypoglycaemia poses serious health risks and can be a significant barrier to achieving glycaemic control.(13) Between week 104 and week 208, mean HbA1c gradually increased toward baseline levels in both treatment groups.”
Background
Cited by
Colacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.04.006 · Cited by 94
Dicembrini, I., Nreu, B., Mannucci, E., & Monami, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13745 · Cited by 85
“A total of 27 trials fulfilling the inclusion criteria was identified (Figure S1 and Table S1).1-3,11-33 The retrieved trials comprised 27 744 and 20 441 patients in SGLT-2 inhibitor and comparator groups, respectively, with a mean duration of treatment of 84 weeks.”
BackgroundSfairopoulos, D., Zhang, N., Wang, Y., Chen, Z., Letsas, K. P., Tse, G., Li, G., Lip, G. Y. H., Liu, T., & Korantzopoulos, P. (2022) · EP Europace · doi:10.1093/europace/euab177 · Cited by 76
Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01103-9 · Cited by 39
Metadata
- Authors
- Ridderstråle, M., Rosenstock, J., Andersen, K. R., Woerle, H. J., Salsali, A., & on behalf of the EMPA‐REG H2H‐SU trial investigators
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-08-07
- Volume
- 20
- Issue
- 12
- Pages
- 2768-2777
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2809903778
- Cited by
- 51
- References
- 5
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial. https://app.cochat.ai/papers/10.1111/dom.13457
- The paper
- Ridderstråle, M., Rosenstock, J., Andersen, K. R., Woerle, H. J., Salsali, A., & on behalf of the EMPA‐REG H2H‐SU trial investigators. (2018). Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.